Rabies treatment debate turns against the Milwaukee Protocol

The latest turn in the long-running rabies treatment debate is a blunt one: the Milwaukee Protocol is being written off by some infectious disease experts as a failed approach that should finally be abandoned. Scott Weese's January 12, 2026, Worms & Germs summary pointed readers to a 2025 Clinical Infectious Diseases viewpoint that argued the protocol's reputation has outlasted its evidence, despite nearly two decades of use after the first widely publicized survival in Milwaukee. (wormsandgermsblog.com)

That history matters because the protocol changed how clinicians and the public talked about rabies. After Jeanna Giese survived rabies in 2004, the induced-coma, multi-drug approach became a symbol of possible rescue in a disease long considered almost uniformly fatal. But skepticism has been building for years. A 2015 commentary in The Pediatric Infectious Disease Journal said the Milwaukee Protocol was no longer valid, and the 2025 CID article argues the same case with newer literature, stricter definitions of survival, and a closer look at what later “successes” actually involved. (pubmed.ncbi.nlm.nih.gov)

The key critique is that the protocol's individual components have not held up. In the 2025 viewpoint, author Charles Rupprecht Jackson says ketamine, ribavirin, and amantadine have not shown convincing efficacy for treating rabies, and he argues that no antiviral agent has been proven effective once clinical disease is established. He also says claims of numerous protocol-linked survivors have not been backed by high-quality published case reports, while at least 64 failures have been reported. Just as important, the paper argues that many documented survivors in recent years received critical care without the core elements of the Milwaukee Protocol, suggesting that supportive ICU care, not the protocol itself, may explain the limited survival seen in rare cases. (academic.oup.com)

The pushback came quickly. In a letter published later in 2025, Rodney Willoughby, the protocol's main proponent, argued that reports of its demise are premature. He said 18 laboratory-confirmed survivors have been validated by health authorities, that many cases remain unpublished because they occurred in low- and middle-income countries, and that aggregate intention-to-treat data show improved survival compared with contemporary controls. At the same time, his letter conceded an important point: long-term survival statistics will require a clinical trial. That leaves the field with a live controversy, but not a settled rescue strategy. (academic.oup.com)

For veterinary professionals, the bigger picture hasn't changed. Rabies is still overwhelmingly a disease where prevention decides the outcome. CDC says infection is nearly universally fatal if post-exposure prophylaxis isn't given before symptoms start. In the U.S., bats remain the leading source of human rabies cases; CDC's 2026 MMWR on two 2024 deaths in Minnesota and California found both patients had recognized bat encounters but did not seek risk assessment or PEP before symptom onset. That is the practical lesson veterinary teams know well: once clinical rabies is suspected, the window for effective intervention has usually closed. (cdc.gov)

Globally, the stakes are still enormous. CDC says nearly 70,000 people die from rabies each year, and WOAH, WHO, FAO, and partners continue to work toward the “Zero by 30” target of ending human deaths from dog-mediated rabies by 2030. For clinics, shelters, and public health veterinarians, that means the core tools remain dog vaccination, wildlife exposure counseling, bite investigation, laboratory confirmation, and fast communication with human health authorities. It also reinforces why conversations with pet parents about overdue rabies vaccines, bat encounters, and reporting bites still matter, even in countries where human rabies is rare. (cdc.gov)

Why it matters: The demise of the Milwaukee Protocol, whether one views it as overdue or disputed, shifts attention back to where veterinary medicine has the most leverage: prevention, surveillance, and One Health coordination. The danger of a high-profile treatment narrative is that it can blur a harder truth for clients and even some clinicians, which is that rabies outcomes depend far more on vaccination and immediate post-exposure action than on heroic ICU measures after symptoms appear. For veterinary teams, this story is less about human critical care than about preserving urgency around animal vaccination, exposure assessment, and public messaging. (academic.oup.com)

What to watch: The next signal will be whether any professional body, registry, or research group publishes stronger comparative data, updated treatment guidance, or a formal trial design, but until then the field is likely to keep moving away from protocol-driven rescue and toward clearer messaging that rabies control starts before illness begins. (academic.oup.com)